Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter Study
Not Applicable
Completed
- Conditions
- The study is an observational study and aims to evaluate the clinical outcomes and classify relevant prognostic factors to measure induction response among high risk neuroblastoma patients in Thailandhigh risked neuroblastoma,topotecan,induction therapy,treatment response,prognostic factor,treatment-related toxicity
- Registration Number
- TCTR20190602002
- Lead Sponsor
- Phramongkutklao Hospital and College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 107
Inclusion Criteria
The study’s inclusion criteria include patients less than 18 years of age who had a new diagnosis of high risk neuroblastoma stratified as per the International Neuroblastoma Risk Group Staging System (INRGSS).
Exclusion Criteria
Patients contra-indicated for topotecan or receiving a diagnosis of refractory or relapsed neuroblastoma
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical outcomes of high risk neuroblastoma patients 2016-2017 Mean with standard deviation for continuous variables; frequency and percentage for categorical vari
- Secondary Outcome Measures
Name Time Method Prognostic factors to predict treatment response among neuroblastoma patients 2016-2017 Univariate and multivariate analyses ,Treatment related toxicity among neuroblastoma patients 2016-2017 Frequency and percentage for categorical variables